BioArctic AB (BRCTF)
20.00
+6.34
(+46.45%)
USD |
OTCM |
Nov 14, 15:33
BioArctic Revenue (Quarterly): 4.673M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.673M |
| March 31, 2024 | 2.858M |
| December 31, 2023 | 1.038M |
| September 30, 2023 | 19.36M |
| June 30, 2023 | 0.2575M |
| March 31, 2023 | 37.75M |
| December 31, 2022 | 0.1957M |
| September 30, 2022 | 20.81M |
| June 30, 2022 | 0.4333M |
| March 31, 2022 | 0.4012M |
| December 31, 2021 | 0.5328M |
| September 30, 2021 | 0.4576M |
| June 30, 2021 | 0.8699M |
| March 31, 2021 | 0.8571M |
| December 31, 2020 | 0.9724M |
| September 30, 2020 | 1.192M |
| Date | Value |
|---|---|
| June 30, 2020 | 0.7248M |
| March 31, 2020 | 3.788M |
| December 31, 2019 | 2.752M |
| September 30, 2019 | 2.152M |
| June 30, 2019 | 18.14M |
| March 31, 2019 | 6.919M |
| December 31, 2018 | 56.96M |
| September 30, 2018 | 10.51M |
| June 30, 2018 | 6.042M |
| March 31, 2018 | 6.454M |
| December 31, 2017 | 6.132M |
| September 30, 2017 | 3.875M |
| June 30, 2017 | 3.636M |
| March 31, 2017 | 2.933M |
| December 31, 2016 | 10.45M |
| September 30, 2016 | 0.1388M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.1957M
Minimum
Dec 2022
37.75M
Maximum
Mar 2023
5.259M
Average
0.9724M
Median
Dec 2020
Revenue (Quarterly) Benchmarks
| Abliva AB | -- |
| Oncopeptides AB | 0.26M |
| BioInvent International AB | 1.23M |
| Hansa Biopharma AB | 4.689M |
| Camurus AB | 46.21M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.415M |
| Total Expenses (Quarterly) | 11.78M |
| EPS Diluted (Quarterly) | -0.0722 |
| Enterprise Value | 1.160B |
| Gross Profit Margin (Quarterly) | 90.35% |
| Profit Margin (Quarterly) | -137.3% |
| Earnings Yield | -0.49% |
| Normalized Earnings Yield | -0.4869 |